Sugi Predict

Sugi Predict / Targets / DPP7

DPP7

Dipeptidyl peptidase 2 · Q9UHL4 · DPP7 on Sugi Atlas →

103,476 patent compounds predicted against DPP7, 42,322 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Talabostat Talabostat (SCHEMBL393024) 1.00 18/20
Gosogliptin Gosogliptin (SCHEMBL197108) 1.00 14/20
SCHEMBL27005 SCHEMBL27005 0.38 13/20
Caprolactam Caprolactam (SCHEMBL388930) 0.51 12/20
Dutogliptin Dutogliptin (SCHEMBL164106) 0.72 11/20
SCHEMBL243605 SCHEMBL243605 0.63 11/20
SCHEMBL419142 SCHEMBL419142 0.36 11/20
SCHEMBL353709 SCHEMBL353709 1.00 10/20
SCHEMBL356202 SCHEMBL356202 1.00 10/20
SCHEMBL388929 SCHEMBL388929 1.00 10/20
SCHEMBL392505 SCHEMBL392505 1.00 10/20
Isoleucine Isoleucine (SCHEMBL391313) 0.70 10/20
SCHEMBL369324 SCHEMBL369324 0.36 10/20
SCHEMBL369325 SCHEMBL369325 0.36 10/20
SCHEMBL297708 SCHEMBL297708 0.63 9/20
SCHEMBL355114 SCHEMBL355114 0.63 9/20
SCHEMBL145916 SCHEMBL145916 0.63 9/20
SCHEMBL358119 SCHEMBL358119 0.44 9/20
SCHEMBL363001 SCHEMBL363001 0.44 9/20
Lysine Lysine (SCHEMBL121844) 0.42 9/20

Clinical trials — most relevant to DPP7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats PHASE4COMPLETED
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes PHASE4UNKNOWN
Incretins in Impaired Fasting Glucose PHASE4COMPLETED
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients) PHASE4COMPLETED
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors PHASE4UNKNOWN
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion PHASE4COMPLETED
Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes PHASE4UNKNOWN
Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI PHASE4WITHDRAWN
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors PHASE4COMPLETED
Correlation Between Plasma- and Endothelial DPP-4 Activity PHASE4COMPLETED
The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes PHASE4COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes PHASE3COMPLETED
Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes PHASE3COMPLETED
Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients PHASE3ENROLLING_BY_INVITATION
Sitagliptin and Endothelial Dysfunction PHASE3UNKNOWN
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients PHASE3UNKNOWN
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis PHASE3COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency PHASE2COMPLETED
Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers PHASE1UNKNOWN
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation nanCOMPLETED
The Incretin Effect in Patients With Kidney Impairment nanCOMPLETED
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation nanUNKNOWN
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects nanUNKNOWN
Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass nanCOMPLETED
DBLG1 System With TERUMO MEDISAFE WITH Insulin Pump Trial nanCOMPLETED
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure nanCOMPLETED
Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DPP7 binder may also engage these)

ProteinNameSimilarity
Q9EPB1 — 0.971 Q9EPB1 →
Q9ET22 — 0.967 Q9ET22 →
Q9GZM7 — 0.952 Q9GZM7 →
LCAT Phosphatidylcholine-sterol acyltransferase 0.951 landscape →
P53761 — 0.950 P53761 →
Q6XPZ3 — 0.950 Q6XPZ3 →
Q08758 — 0.948 Q08758 →
F1NZI4 — 0.947 F1NZI4 →
O97583 — 0.946 O97583 →
Q9QXE5 — 0.946 Q9QXE5 →
SMPD1 Sphingomyelin phosphodiesterase 0.946 landscape →
Q9EQT5 — 0.945 Q9EQT5 →
Q0VD19 — 0.945 Q0VD19 →
O00587 — 0.944 O00587 →
ENTPD2 Ectonucleoside triphosphate diphosphohydrolase 2 0.944 landscape →
O35795 — 0.944 O35795 →
Q5IS64 — 0.943 Q5IS64 →
Q04519 — 0.943 Q04519 →
Q32M88 — 0.942 Q32M88 →
Q99JR5 — 0.942 Q99JR5 →
Q9NQE7 — 0.942 Q9NQE7 →
P52850 — 0.942 P52850 →
Q9BZG2 — 0.940 Q9BZG2 →
PLOD3 Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3 0.940 landscape →
Q5T4B2 — 0.940 Q5T4B2 →
Q5R6K5 — 0.940 Q5R6K5 →
P52849 — 0.939 P52849 →
Q8NCC3 — 0.939 Q8NCC3 →
A7MB73 — 0.939 A7MB73 →
Q9TUD6 — 0.939 Q9TUD6 →